PT  - JOURNAL ARTICLE
AU  - Stefan Thurner
AU  - Peter Klimek
AU  - Rudolf Hanel
TI  - Why are most COVID-19 infection curves linear?
AID  - 10.1101/2020.05.22.20110403
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.22.20110403
4099  - http://medrxiv.org/content/early/2020/05/24/2020.05.22.20110403.short
4100  - http://medrxiv.org/content/early/2020/05/24/2020.05.22.20110403.full
AB  - Many countries have passed their first COVID-19 epidemic peak. Traditional epidemiological models describe this as a result of non-pharmaceutical interventions that pushed the growth rate below the recovery rate. In this new phase of the pandemic many countries show an almost linear growth of confirmed cases for extended time-periods. This new containment regime is hard to explain by traditional models where infection numbers either grow explosively until herd immunity is reached, or the epidemic is completely suppressed (zero new cases). Here we offer an explanation of this puzzling observation based on the structure of contact networks. We show that for any given transmission rate there exists a critical number of social contacts, Dc, below which linear growth and low infection prevalence must occur. Above Dc traditional epidemiological dynamics takes place, as e.g. in SIR-type models. When calibrating our corresponding model to empirical estimates of the transmission rate and the number of days being contagious, we find Dc ~ 7.2. Assuming realistic contact networks with a degree of about 5, and assuming that lockdown measures would reduce that to household-size (about 2.5), we reproduce actual infection curves with a remarkable precision, without fitting or fine-tuning of parameters. In particular we compare the US and Austria, as examples for one country that initially did not impose measures and one that responded with a severe lockdown early on. Our findings question the applicability of standard compartmental models to describe the COVID-19 containment phase. The probability to observe linear growth in these is practically zero.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Austrian Science Promotion Agency, FFG project under 857136, the Austrian Science Fund FWF under P29252, the WWTF under COV 20-017, and the Medizinisch-Wissenschaftlichen Fonds des Burgermeisters der Bundeshauptstadt Wien under CoVid004.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics approval necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used is openly available from the infections database at CSSE at Johns Hopkins University. https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series